Loading stock data…
Inhibikase Therapeutics (IKT)
$1.93+0.02 (+1.05%)
After Hours$1.90-0.03 (-1.55%)· Last close Jun 29
Inhibikase Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inhibikase Therapeutics, Inc. in the Healthcare sector is trading at $1.93 with a market capitalization of $221M. Wall Street consensus targets $5.88 (8 analysts), implying a +204.4% move over the next 12 months. The stock is currently 15% below its 52-week high of $2.26, remaining 12.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +204.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.22M↓ | -$13.13M↑ | -$13.26M↓ | -$11.19M↑ | -$15.76M |
| Net Income | -$16.38M↓ | -$12.73M↓ | -$11.93M↓ | -$9.92M↑ | -$13.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threaten...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$221.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.40%
Volume
Today's trading volume
499,990
Recent News
Bank of America Predicts Up to 240% Jump for These 2 ‘Strong Buy’ Stocks
The stock market has been treading water so far this year, with the S&P 500 up roughly 1% while the Nasdaq has slipped 1.5%. Tech stocks have struggled to regain last year’s momentum as investors reassess the durability of AI-driven spending, the margin impact of massive capital expenditures, and whether growth rates can justify the premium multiples many companies still command. That skepticism toward richly valued mega-cap tech has pushed investors to look elsewhere for returns, and biotech ha
Sands Capital Opens $10 Million ServiceTitan Position
ServiceTitan offers cloud software for field service management, generating recurring revenue from a broad base of service professionals.
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company
Key Insights The considerable ownership by individual investors in Inhibikase Therapeutics indicates that they...
Inhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70m
In the last year, multiple insiders have substantially increased their holdings of Inhibikase Therapeutics, Inc...